Groundbreaking research shows psilocybin therapy equals traditional antidepressants in treating depression with potential ...

Depression speeds up physical illness. A study shows adults with depression develop conditions 30% faster. Read more.

Psilocybin therapy significantly decreased moderate to severe symptoms of depression in clinicians after frontline work ...

However, some believe ECT affects neurotransmitters, hormones, brain structure, and cell regeneration, contributing to an improvement in depression. Learn more about ECT. During shock therapy ...

Supernus Pharmaceuticals may have had a potential path forward for its depression drug candidate cut off after the asset ...

For older adults with type 2 diabetes (T2D), use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associate ...

The following is a summary of “Comparative effectiveness of short-term psychodynamic psychotherapy and cognitive behavioral ...

Creatine supplementation could lead to a faster reduction in depressive symptoms compared to traditional antidepressants,' ...

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) revealed the topline data from the Phase 2b study of SPN-820 in adults with ...

Depression is not just a mental health issue it’s a condition that affects the entire body and can accelerate the onset of ...

Among 13,711 matched pairs, GLP-1 receptor agonist users had a 10% lower risk for depression compared with DPP-4 inhibitor ...